PRCT
$27.36
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
Intraday
Recent News
Procept BioRobotics price target lowered to $30 from $47 at Truist
Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for sustainable growth of 25% or more through 2027, highlighted by ongoing penetration into the BPH opportunity, strategy changes geared towards increasing utilization and more visibility into the business, the analyst tells investors in a research note.Claim 70% Off TipRanks PremiumUnlock hedge fund-l
PROCEPT BioRobotics Investor Day: 2026 growth targets, higher ASPs, and profitability roadmap
PROCEPT BioRobotics (NASDAQ:PRCT) used its 2026 Analyst Day to outline what management characterized as a large, underpenetrated opportunity in benign prostatic hyperplasia (BPH), a developing adjacent opportunity in prostate cancer, and a set of commercial and financial initiatives aimed at acceler
A Look At PROCEPT BioRobotics (PRCT) Valuation After Q4 Revenue Miss And Softer 2026 Outlook
PROCEPT BioRobotics (PRCT) is back in focus after its Q4 2025 revenue miss, softer 2026 outlook, and sharp share price reaction, even as management pointed to strong procedure growth and major commercial changes. See our latest analysis for PROCEPT BioRobotics. The recent selloff has been sharp, with a 7 day share price return of 16.79% and a 30 day share price return of 24.42%, adding to a 1 year total shareholder return of 64.73%. This combination signals fading momentum despite ongoing...
Robotics Play Procept Biorobotics Plummets On Hard-To-Stomach Update
Procept Biorobotics stock crashed Thursday on a hard-to-stomach update that included light fourth-quarter sales and a 2026 guidance cut.
PROCEPT BioRobotics Corporation Q4 2025 Earnings Call Summary
Moby summary of PROCEPT BioRobotics Corporation's Q4 2025 earnings call